某年度美国外用止痛药市场分析报告课件.pptVIP

? Major “Non-Natural Product” OTC Brands主要OTC品牌? Direct Natural Product Competitors: 主要天然产品竞争对手? Tiger Balm Case: Early Disappointment, Later Success虎牌早期不满意后来较成功的案例? Capsasin Brands Case: Early Success, LaterDisappointment 开普莎早期成功，后期不满意? O24 Case: Failure O24 的失败案例? ALCiS Case? Conclusion 结论 ? Major Non-Natural Product OTC Brands? Direct Natural Product Competitors:? Tiger Balm Case: Early Disappointment, Later? Capsasin Brands Case: Early Success, Later? O24 Case: Failure? ALCiS Case? Conclusion While the overall OTC and RX pain medicationmarket combined is huge…镇痛药的处方药与OTC整体市场很大? In 2003, the TOTAL U.S OTC and RX market forpain products was $12 billion： 03年120亿美元? By some measures, the US pain market alone islarger than the entire Chinese pharmaceuticalmarket in 2003Source: /2005/03/31/0001144204-05-009623/Section2.asp …the market for topical OTC is only $500 M -$700 M 外用OTC药5-7亿美元? However, sales of OTC topical analgesics are? Prescription products, such as opioids and“NSAIDs” such as COX-2 inhibitors constitutemost of the market. 口服的解热镇痛药如非甾抗炎药绝对为 主? The market for COX-2’s alone (such as Vioxxand Celebrex) exceeds $5,000,000,000 (RMB40,000,000,000). 仅环氧化酶2抑制剂药50亿美元Source: /2006/07/13/0001193125-06-146047/Section3.asp However there is an opportunity for OTC productsas the reputation of COX-2s suffers 由于环氧化酶2的声誉正在降低，OTC产品仍有机会? Recent recalls of these prescription medicationscombined with Qizheng’s efficaciousness intreating pain sufferers may increase the marketopportunity.? Much of that estimated prescription painreliever marketplace might be susceptible topenetration by OTC products, such as that ofQizhengs.Source: Swiss Medica 2003 Annual Report In addition, the OTC analgesic market isfragmented, there are a few major brands OTC的镇痛药市场分散? In the topical market, Qizheng’s competitors areproducts such as, but not limited to Ben Gayand Ice Hot, with the total combined marketsales estimated to be $250 million in 2002.? 奇正的竞争对手除“奔盖”和“冰热”外还有其它许多小品牌? Behind these two